Ampersand Biomedicines enables a new way of programming medicines that work precisely where needed in the body and nowhere else. The company's computationally powered Address, Navigate, Determine (AND) Platform identifies ideal addresses for drug localization and informs the design of AND-Body Therapeutics that have the optimal therapeutic effect. The result is smarter biologic medicines that target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded by Flagship Pioneering in 2021.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/19/25 | $65,000,000 | Series B |
Avak Kahvejian Eli Lilly and Company Flagship Pioneering | undisclosed |
